Table 1.
Characteristics of 100 patients with AML
| Variable at diagnosis | APL patients (n = 40) | Non-APL patients (n = 60) |
|---|---|---|
| N (%) | N (%) | |
| Gender | ||
| Female | 25 (62.5) | 30 (50) |
| Male | 15 (37.5) | 30 (50) |
| Age | ||
| < 50 | 30 (75.0) | 35 (58.3) |
| ≥ 50 | 10 (25.0) | 25 (41.7) |
| Leukocyte counts, ×109/L | ||
| < 10 | 35 (87.5) | 45 (75.0) |
| ≥ 10 | 5 (12.5) | 15 (25.0) |
| Risk group | ||
| Low/intermediate | 35 (87.5) | – |
| High | 5 (12.5) | – |
| Treatment | ||
| ATO + ATRA | 38 (95.0) | – |
| Cytarabine + ATRA | 2 (5.0) | – |
Abbreviations: AML acute myeloid leukaemia, APL acute promyelocytic leukaemia, ATO Arsenic Trioxide, ATRA all-trans retinoic acid